Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy - Takeaways - MDSpire

Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy

  • By

  • Severin Rodler

  • Dina Danninger

  • Lennert Eismann

  • Philipp Maximilian Kazmierczak

  • Friedrich Jokisch

  • Minglun Li

  • Armin Becker

  • Alexander Kretschmer

  • Christian Stief

  • Thilo Westhofen

  • April 18, 2024

  • 0 min

Share

  • 1

    Salvage radical prostatectomy (sRP) offers long-term cancer control with 5-year survival rates up to 95% for recurrent prostate cancer.

  • 2

    Urinary incontinence rates post-sRP have improved, with recent studies reporting continence rates up to 90% after surgery.

  • 3

    Health-related quality of life (HRQOL) data following sRP is limited, emphasizing the need for patient-reported outcome measures.

  • 4

    No significant differences in HRQOL were found between patients who underwent sRP after radiotherapy or focal therapy.

  • 5

    The largest declines in HRQOL subscales were observed in social and role functioning, particularly in the radiotherapy group.

Original Source(s)

Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy

  • by Severin Rodler, Dina Danninger, Lennert Eismann, Philipp Maximilian Kazmierczak, Friedrich Jokisch, Minglun Li, Armin Becker, Alexander Kretschmer, Christian Stief, Thilo Westhofen

  • April 18, 2024

Related Content

Polyethylene glycol-based hydrogel rectal spacers for prostate brachytherapy: a systematic review with a focus on technique

Prostate Cancer Conference Highlights from ASCO GU 2025

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from GU ASCO 2025. This video highlights updates in mCRPC and oligometastatic prostate cancer trials.

  • March 3, 2025

  • 1 min
Beyond Treatment Volume: When Pelvic Radiotherapy May Still Matter in High-Risk Localised Prostate Cancer